5th Circuit Court Pauses FDA's Mail-Order Abortion Drug Permissions

The 5th Circuit Court of Appeals has granted Louisiana's request to pause the U.S. Food and Drug Administration's (FDA) permissions for mail-order abortion drugs, specifically mifepristone, citing concerns over the safety of women and unborn children. This ruling comes amid a lawsuit that argues the FDA's relaxed regulations on the abortion pill pose significant risks.

Explainer 5th Circuit Court Halts FDA’s Mail-Order Abortion Drug Permissions Citing Safety Concerns

The core tension lies in the balance between access to abortion medications and the potential health risks associated with their use, particularly when obtained without medical supervision. Critics argue that the financial interests of drug manufacturers, such as Danco Laboratories, overshadow the health concerns raised by Louisiana and other plaintiffs.

Danco Laboratories, the maker of mifepristone, acknowledged in court that its “substantial financial interest” in selling abortion drugs should be considered in the legal proceedings. However, the 5th Circuit panel found that the potential financial losses for Danco were minor compared to the irreparable harm Louisiana claimed it would face without the stay. The court stated, “Louisiana’s financial harms are also irremediable.”

Background on the Case

The lawsuit from Louisiana, supported by abortion pill poisoning survivor Rosalie Markezich, highlights the dangers associated with mail-order abortion pills, which can be obtained without a doctor's visit. The plaintiffs argue that the relaxed policies have led to increased health risks for women, including severe side effects such as hemorrhage and infection. According to a recent analysis, more than one in ten women who take mifepristone experience serious adverse events.

The 5th Circuit's ruling emphasized that the risks associated with mail-order mifepristone are significant, particularly for women who may be further along in their pregnancies than the FDA's guidelines recommend. The court noted that the risk of life-threatening side effects is at least 22 times higher than what Danco and the FDA have claimed.

Financial Implications

In addition to health concerns, Louisiana's lawsuit also pointed to the financial burden on taxpayers for emergency medical care related to complications from mifepristone. The court agreed that the state demonstrated ongoing financial harm due to the FDA's policies, which undermine state laws protecting the unborn.

Danco Laboratories, in its defense, argued that the state waited too long to file the lawsuit and that a stay would harm its business operations. However, the court found that the company’s financial interests do not outweigh the public's interest in ensuring safe medical practices. The panel stated, “To the contrary, a stay would only pause a method of prescribing mifepristone that began five years ago.”

Public Opinion and Legislative Response

Polling indicates that a majority of likely voters support stricter regulations on abortion pills, with many advocating for reinstating in-person doctor visits as a requirement for obtaining mifepristone. This sentiment is echoed by several Republican lawmakers who have called on the FDA to roll back the relaxed abortion pill policies implemented under the Biden administration.

Senator Josh Hawley has introduced legislation to ban mifepristone and provide legal remedies for those harmed by the drug. In a letter to Danco, GOP Senators expressed concerns about the company’s compliance with the FDA's Risk Evaluation and Mitigation Strategy (REMS), suggesting that Danco is not effectively ensuring that the requirements are met.

Despite the ongoing legal battles and public outcry, officials from the FDA have not yet indicated plans to reinstate previous safeguards, such as mandatory in-person consultations. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary have pledged to review the data related to the abortion pill but have not provided a timeline for when this review will be completed.

As the legal proceedings continue, the implications of the 5th Circuit's ruling may have lasting effects on access to abortion medications and the regulatory landscape surrounding them. Women like Rosalie Markezich remain at risk of the injuries and complications linked to mifepristone, raising ongoing concerns about the safety of mail-order abortion drugs.